MOTS-c
Molecular Research Profile · Target purity > 99.0% · Half-life Intermediate
Mitochondrial-derived peptide (MDP) encoded in the 12S rRNA region of mtDNA. Regulates metabolic flexibility, insulin sensitivity, and nuclear-mitochondrial crosstalk — a key mediator of the mitochondrial stress response.
Mechanism of Action
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide — one of a growing class of bioactive peptides encoded within mitochondrial DNA rather than nuclear DNA. This is significant because it represents a direct line of communication from mitochondria to the nucleus: MOTS-c translocates to the nucleus under metabolic stress conditions and regulates nuclear gene expression, particularly genes involved in glucose and fatty acid metabolism.
Mechanistically, MOTS-c acts through at least three pathways: (1) AMPK activation via direct binding to the folate cycle enzyme MTHFD2, increasing AICAR levels and triggering AMPK phosphorylation — this enhances glucose uptake and fatty acid oxidation independent of insulin signaling; (2) SIRT1 activation via NAD+-dependent deacetylation, promoting PGC-1α-mediated mitochondrial biogenesis; (3) nuclear gene regulation via direct chromatin interaction, upregulating antioxidant response elements (AREs) and suppressing NF-κB-driven inflammation.
What makes MOTS-c unique among research peptides is its mitochondrial origin: it is one of the few peptides that signals "mitochondrial health status" to the rest of the cell, making it a key research tool in mitohormesis and metabolic flexibility studies.
Research History & Context
MOTS-c was discovered in 2015 by Dr. Pinchas Cohen's lab at the University of Southern California, as part of a systematic search for open reading frames within mitochondrial DNA that could encode functional peptides. The discovery challenged the long-held assumption that mtDNA encodes only 13 proteins (all OXPHOS subunits), revealing a hidden peptide layer of mitochondrial gene expression.
Mouse studies demonstrated that MOTS-c administration prevents age-dependent and high-fat-diet-induced insulin resistance, increases skeletal muscle glucose uptake, and enhances physical endurance. Human studies (observational) have correlated lower MOTS-c levels with obesity and type-2 diabetes. The peptide has generated significant interest in the longevity research community as a potential mediator of the metabolic benefits of exercise, and as a tool for studying mitochondrial-nuclear communication pathways.
Storage & Handling
Store lyophilized MOTS-c at -20°C, protected from light. Stability data is more limited than for older peptides; conservative protocols recommend use within 12 months. The peptide's secondary structure includes a β-turn motif stabilized by hydrophobic interactions — avoid excessive agitation during reconstitution.
Reconstituted MOTS-c should be stored at 2–8°C and used within 14 days. Due to the 2–3× weekly research protocol, a single 10mg vial typically covers 1–2 weeks of research. The solution is clear and colorless; any turbidity indicates aggregation and the vial should be discarded.
Reconstitution & Research Dosing
For MOTS-c, the standard laboratory reconstitution is 2.0 ml BAC water for 10mg vial. A typical research study window uses 5 - 10 mg / 2-3× weekly.
For a 10mg MOTS-c research vial, add 2.0 ml BAC water (5.0 mg/ml = 5 mg per 1.0 ml). The relatively high research dose means injection volumes are larger than for microgram-range peptides — use a standard 1ml syringe rather than an insulin syringe for doses >5 mg. MOTS-c has been researched both as monotherapy and in combination with NAD+ for synergistic metabolic effects.
Use the Reconstitution Calculator for exact syringe units →Explore Related Research Compounds
Research Use Only (RUO): MOTS-c is discussed strictly as an in-vitro laboratory research compound. Nothing on this page constitutes human or clinical administration guidance. Always verify purity through independent third-party HPLC/MS analysis before use.